4//SEC Filing
Camardo Daniel A. 4
Accession 0001209191-21-023819
CIK 0001492426other
Filed
Mar 30, 8:00 PM ET
Accepted
Mar 31, 5:11 PM ET
Size
11.9 KB
Accession
0001209191-21-023819
Insider Transaction Report
Form 4
Camardo Daniel A.
EVP and President, U.S.
Transactions
- Sale
Ordinary Shares
2021-03-30$84.97/sh−4,594$390,352→ 39,403 total - Sale
Ordinary Shares
2021-03-30$86.87/sh−3,517$305,522→ 32,900 total - Sale
Ordinary Shares
2021-03-30$83.58/sh−1,803$150,695→ 43,997 total - Sale
Ordinary Shares
2021-03-30$85.88/sh−2,986$256,438→ 36,417 total
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2021.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.23 to $84.095 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.53 to $85.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.55 to $86.545 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.60 to $87.33 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Horizon Therapeutics Public Ltd Co
CIK 0001492426
Entity typeother
Related Parties
1- filerCIK 0001820365
Filing Metadata
- Form type
- 4
- Filed
- Mar 30, 8:00 PM ET
- Accepted
- Mar 31, 5:11 PM ET
- Size
- 11.9 KB